Dyne Therapeutics (DYN, $42.7) was one of top quarterly gainers, jumping +7 to $42.7 per share. A.I.dvisor analyzed 873 stocks in the Biotechnology Industry over the last three months, and discovered that of them (6) charted an Uptrend while of them (3) trended down. A.I.dvisor found 170 similar cases when DYN's price went up within three months. In out of those 170 cases, DYN's price went down during the following month. Based on these historical data, A.I. thinks the odds of an Uptrend reversal for DYN are